Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Herder

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
International Journal of Health Services : Planning, Administration, Evaluation|December 22, 2020
Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19Joel Lexchin, Janice Graham, Matthew Herder, et al.
International Journal of Health Policy and Management|August 14, 2023
Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 PandemicIpek Eren Vural, Matthew Herder, Agnieszka Doll, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 31, 2024
"A Most Equitable Drug": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug DevelopmentQuinn Grundy, Chantal Campbell, Ridwaanah Ali, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 12, 2014
Regulating prescription drugs for patient safety: does Bill C-17 go far enough?Matthew Herder, Elaine Gibson, Janice Graham, et al.
BMJ Evidence-Based Medicine|March 21, 2023
US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeuticsAshley Eadie, Andrea MacGregor, Joshua Wallach, et al.
Human Vaccines & Immunotherapeutics|April 1, 2015
Against vaccine assay secrecyMatthew Herder, Todd F Hatchette, Scott A Halperin, et al.
Health Affairs Scholar|November 17, 2025
Flexibility over rigor: stakeholder acceptance of the limitations of confirmatory studies following accelerated approvalHolly Fernandez Lynch, Sejin Lee, Matthew Herder, et al.
JAMA Network Open|July 25, 2020
Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015Andrea MacGregor, Audrey D Zhang, Joshua D Wallach, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 19, 2022
Reducing barriers to accessing administrative data on SARS-CoV-2 vaccination for researchAndrew D McRae, Patrick Archambault, Patrick Fok, et al.
JAMA Health Forum|June 9, 2023
Extending the US Food and Drug Administration's Postmarket AuthoritiesHolly Fernandez Lynch, Rachel E Sachs, Sejin Lee, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
International Journal of Health Services : Planning, Administration, Evaluation|December 22, 2020
Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19Joel Lexchin, Janice Graham, Matthew Herder, et al.
International Journal of Health Policy and Management|August 14, 2023
Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 PandemicIpek Eren Vural, Matthew Herder, Agnieszka Doll, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 31, 2024
"A Most Equitable Drug": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug DevelopmentQuinn Grundy, Chantal Campbell, Ridwaanah Ali, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 12, 2014
Regulating prescription drugs for patient safety: does Bill C-17 go far enough?Matthew Herder, Elaine Gibson, Janice Graham, et al.
BMJ Evidence-Based Medicine|March 21, 2023
US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeuticsAshley Eadie, Andrea MacGregor, Joshua Wallach, et al.
Human Vaccines & Immunotherapeutics|April 1, 2015
Against vaccine assay secrecyMatthew Herder, Todd F Hatchette, Scott A Halperin, et al.
Health Affairs Scholar|November 17, 2025
Flexibility over rigor: stakeholder acceptance of the limitations of confirmatory studies following accelerated approvalHolly Fernandez Lynch, Sejin Lee, Matthew Herder, et al.
JAMA Network Open|July 25, 2020
Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015Andrea MacGregor, Audrey D Zhang, Joshua D Wallach, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|July 19, 2022
Reducing barriers to accessing administrative data on SARS-CoV-2 vaccination for researchAndrew D McRae, Patrick Archambault, Patrick Fok, et al.
JAMA Health Forum|June 9, 2023
Extending the US Food and Drug Administration's Postmarket AuthoritiesHolly Fernandez Lynch, Rachel E Sachs, Sejin Lee, et al.
Pageof 6